Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Mayo Clinic

Sites in Rochester, MN

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 5:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1824
Shown on this page
12
Current sort
Recently updated
Campus scope
Mayo Clinic, Rochester, MN
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Mayo Clinic, Rochester, MN. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 793–804 of 1,824 matching trials with a site at Mayo Clinic, Rochester, MN.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 1Phase 2 Interventional Results available

MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer

NCT02068794
Site status not listed — check the official record
View directory record Official record
Conditions
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Malignant Ovarian Brenner Tumor, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Laboratory Biomarker Analysis, Mesenchymal Stem Cell Transplantation, Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter, Echocardiography, Multigated Acquisition Scan, Biospecimen Collection, Chest Radiography, Single Photon Tomography and Computed Tomography Scan, Computed Tomography, Magnetic Resonance Imaging
Other · Procedure · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 31, 2026, 5:41 AM EDT
Recruiting No phase listed Observational

Trans-Pacific Multicenter Collaborative Study of Minimally Invasive Proximal Versus Total Gastrectomy for Proximal Gastric and Gastroesophageal Junction Cancers

NCT05205343
Status at this site: Active, not recruiting
View directory record Official record
Conditions
Gastrostomy, Gastric, GastroEsophageal Cancer
Interventions
Standard of Care, Control Group
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
2
States / cities
Rochester, Minnesota • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 31, 2026, 5:41 AM EDT
Recruiting Phase 1 Interventional

AAVrh10-PCCA Gene Therapy for Propionic Acidemia

NCT07643844
Status at this site: Recruiting
View directory record Official record
Conditions
Propionic Acidemia
Interventions
AAVrh10-PCCA low dose, AAVrh10-PCCA middle dose, AAVrh10-PCCA high dose
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
6 Months to 2 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 31, 2026, 5:41 AM EDT
Recruiting Phase 4 Interventional

Itraconazole Therapy In Bronchiectasis With Airway Mold

NCT07283497
Status at this site: Recruiting
View directory record Official record
Conditions
Bronchiectasis, Fungal Infection of Upper Respiratory Tract
Interventions
Itraconazole 200 mg
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 31, 2026, 5:41 AM EDT
Recruiting Phase 4 Interventional

The Effect Of Lisinopril On Polycythemia

NCT07594535
Status at this site: Recruiting
View directory record Official record
Conditions
Polycythemia
Interventions
Lisinopril Tablets
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 31, 2026, 5:41 AM EDT
Active, not recruiting Phase 3 Interventional

Intensity-Modulated Proton Beam Therapy or Intensity-Modulated Photon Therapy in Treating Patients With Stage III-IVB Oropharyngeal Cancer

NCT01893307
Site status not listed — check the official record
View directory record Official record
Conditions
Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7
Interventions
Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Photon Beam Radiation Therapy, Proton Beam Radiation Therapy, Quality-of-Life Assessment
Radiation · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2031
U.S. locations
22
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Gainesville, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 31, 2026, 5:41 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Understanding Mechanisms of Normal and Disordered Defecation

NCT03842007
Status at this site: Recruiting
View directory record Official record
Conditions
Constipation
Interventions
Rectal Barostat Study, Fecoflowmetry
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 31, 2026, 5:41 AM EDT
Recruiting Phase 3 Interventional

OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events

NCT07136012
Status at this site: Recruiting
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Olpasiran, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
50 Years to 105 Years
Enrollment
11,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
205
States / cities
Alexander City, Alabama • Birmingham, Alabama • Daphne, Alabama + 170 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 31, 2026, 5:41 AM EDT
Active, not recruiting Phase 3 Interventional

Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma

NCT05602194
Site status not listed — check the official record
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Acute Lymphoblastic Leukemia, BCR-ABL1-Like, Lymphoblastic Lymphoma, Mixed Phenotype Acute Leukemia, T Acute Lymphoblastic Leukemia
Interventions
Biospecimen Collection, Calaspargase Pegol, Levocarnitine, Pegaspargase, Quality-of-Life Assessment
Procedure · Drug · Dietary Supplement + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
15 Years to 40 Years
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
225
States / cities
Birmingham, Alabama • Anchorage, Alaska • Kingman, Arizona + 149 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 31, 2026, 5:41 AM EDT
Recruiting Phase 3 Interventional

Abatacept for the Treatment of Giant Cell Arteritis

NCT04474847
Status at this site: Recruiting
View directory record Official record
Conditions
Giant Cell Arteritis
Interventions
Abatacept, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
50 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
5
States / cities
Rochester, Minnesota • New York, New York • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 31, 2026, 5:41 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Exercise Cardiovascular Magnetic Resonance In Heart Failure With Preserved Ejection Fraction

NCT07401771
Status at this site: Recruiting
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
Exercise Cardiovascular Magnetic Resonance
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 31, 2026, 5:41 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Tool for Improving the Shared Decision-making Process in Patients With Non-small Cell Lung Cancer

NCT06122064
Status at this site: Recruiting
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions
Best Practice, Communication Intervention, Electronic Health Record Review, Survey Administration, Video Recording, Audio Recording
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 31, 2026, 5:41 AM EDT

About this Mayo Clinic institution page

What this page lists
ClinicalTrials.gov records that list Mayo Clinic in Rochester, MN as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by Mayo Clinic at any site, browse by condition, or browse by U.S. city.